Amid tough respiratory competition, AstraZeneca inks Symbicort outcomes-based deals

It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share.

• Source: fiercepharma
• 635
• April 20, 2018